Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME Trial: Antibiotic Regimens for Primary Pseudomonas aeruginosa Infection in Bronchiectasis
2025-524454-34-00Phase 4Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jun 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of colistimethate sodium and ciprofloxacin in bronchiectasis and Pseudomonas aeruginosa airway infection (4 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Microbiological eradication of Pseudomonas aeruginosa at 3 months. Planned start Jun 2026; status: authorised.
02
Drugs
colistimethate sodiumciprofloxacin
03
Conditions
bronchiectasisPseudomonas aeruginosa airway infection
Beyond the preview
Go deeper on 2025-524454-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524454-34-00.